Related Experiment Videos
Studies of c-jun oncogene expression in human breast using a new monoclonal antibody, NCL-DK4
D G Tiniakos1, L E Scott, I P Corbett
1Division of Pathology, School of Pathological Sciences, University of Newcastle upon Tyne, U.K.
Abstract:
A new monoclonal antibody to human c-jun oncoprotein, designated NCL-DK4, has been produced. NCL-DK4 has been proved to be highly effective for use on formalin-fixed, paraffin-embedded tissues, enabling the study of c-jun expression at a cellular level in both normal and neoplastic human tissues. The expression of c-jun oncogene has been examined in normal, benign, and malignant breast tissues, and c-jun-specific immunoreactivity in carcinomas has been related to histological type, tumour grade, c-erbB-2, oestrogen receptor, progesterone receptor, and epidermal growth factor receptor expression. Normal and benign breast tissues showed c-jun-specific immunostaining, which was weaker and in fewer cells compared with the c-jun immunoreactivity observed in breast carcinomas. No relationship was found between the degree of immunostaining and the extent of proliferative changes in benign breast tissues. Ninety per cent of all breast carcinomas studied showed c-jun-specific nuclear staining. There were no statistically significant differences in the intensity of c-jun immunoreactivity among grade I, II, and III infiltrating ductal carcinomas. There was no significant relationship between c-jun oncoprotein expression and c-erbB-2, oestrogen, progesterone, and epidermal growth factor receptor immunoreactivity.
Insights
A new antibody effectively detects c-jun oncoprotein in breast tissues. Elevated c-jun expression is common in breast carcinomas but not linked to specific tumor characteristics.
Area of Science:
- Oncology
- Molecular Biology
- Immunohistochemistry
Background:
- The c-jun oncogene plays a role in cellular processes.
- Understanding c-jun expression is crucial for cancer research.
- A reliable method for detecting c-jun in tissue samples is needed.
Purpose of the Study:
- To develop and validate a monoclonal antibody (NCL-DK4) for human c-jun oncoprotein detection.
- To investigate c-jun expression patterns in normal, benign, and malignant breast tissues.
- To correlate c-jun immunoreactivity with clinicopathological features of breast carcinomas.
Main Methods:
- Production of a novel monoclonal antibody, NCL-DK4, against human c-jun oncoprotein.
- Application of NCL-DK4 for immunohistochemical analysis of formalin-fixed, paraffin-embedded breast tissues.
- Correlation of c-jun staining intensity with histological type, tumor grade, and other receptor expressions (c-erbB-2, ER, PR, EGFR).
Main Results:
- NCL-DK4 demonstrated high efficacy in formalin-fixed, paraffin-embedded tissues.
- Breast carcinomas exhibited stronger and more widespread c-jun nuclear staining compared to normal and benign tissues.
- Ninety percent of breast carcinomas showed c-jun nuclear staining.
- No significant correlation was found between c-jun expression levels and tumor grade, c-erbB-2, ER, PR, or EGFR status.
Conclusions:
- The NCL-DK4 antibody is a valuable tool for studying c-jun expression in breast tissues.
- Elevated c-jun oncoprotein expression is a common feature of breast carcinomas.
- c-jun expression in breast cancer does not appear to be associated with common prognostic markers.